Home / Deep Research / Abetalipoproteinemia

Abetalipoproteinemia

Abetalipoproteinemia Deep Research Fallback

⚠️ Fallback MONDO:0008692

Abetalipoproteinemia Deep Research Fallback

Provider Attempts

  • 2026-05-04T05:24Z: timeout 120 just research-disorder falcon Abetalipoproteinemia timed out with exit code 124 after the provider command was terminated by timeout.
  • 2026-05-04T05:26Z: timeout 120 just research-disorder openai Abetalipoproteinemia timed out with exit code 124 after the provider command was terminated by timeout.

No provider-generated research artifact was available to integrate. Curation therefore proceeded from generated structured Orphanet evidence and fetched PubMed caches, without hand-editing any references_cache/*.md files.

Evidence Scope Used For Curation

  • ORPHA:14 structured record for disease definition, MONDO exact mapping, inheritance, prevalence, MTTP gene association, onset, and HPO phenotype frequencies.
  • PMID:24288038 for the canonical management framework and the mechanism that defective packaging and secretion of apoB-containing lipoproteins underlies abetalipoproteinemia.
  • PMID:30358967 for GeneReviews clinical characteristics, diagnosis/testing, diet and vitamin management, surveillance, and genetic counseling.
  • PMID:10946006 for patient MTTP variant screening and functional evidence that MTP gene defects are the proximal cause of abetalipoproteinemia.
  • PMID:8939939 for functional evidence that an abetalipoproteinemia-associated MTTP missense variant disrupts formation of an active MTP complex with protein disulfide isomerase.
  • PMID:30522860 for clinical evidence that deleterious MTTP variants produce undetectable apoB, extremely low LDL cholesterol, and inability to export apoB-containing lipoproteins from intestine and liver.
  • PMID:18611256 for long-term human clinical reports supporting high-dose fat-soluble vitamin treatment, including vitamin E, with arrest of neuropathy and other complications.

Curation Conclusions

The accepted disease model is MTTP loss of function causing defective intestinal chylomicron assembly and hepatic VLDL assembly, with loss of apoB-containing lipoprotein secretion. This explains the biochemical profile of absent or extremely low apoB lipoproteins, hypocholesterolemia, hypotriglyceridemia, fat malabsorption, and secondary fat-soluble vitamin deficiency. The clinical graph links these defects to ORPHA-supported gastrointestinal, hematologic, retinal, neurologic, hepatic, and biochemical phenotypes. Treatment evidence supports low-fat diet, essential fatty acid supplementation, and high-dose fat-soluble vitamin supplementation as the main management axis.